Latest News
Global Funding Shifts Redraw Life Sciences Innovation Map
The life sciences sector is experiencing a fundamental reshaping of its innovation geography as funding pressures, policy shifts, and geopolitical tensions redraw the competitive landscape across continents. While research funding constraints in the United States...
Latest News
Auxilium and MBI Launch Life Sciences Accelerator Cohort in Worcester
Auxilium and Massachusetts Biomedical Initiatives (MBI) have announced a joint life sciences accelerator cohort in Worcester designed to attract and support founders developing the next generation of healthcare and life sciences technologies. Founders selected for the...
Experimental Alzheimer’s Pill Boosts the Brain’s Cleanup System
Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug...
Communicating Innovation Without Creating Regulatory or Commercial Risk
Biotech companies today face a delicate balancing act: communicating innovation early enough to build credibility and momentum, while avoiding regulatory and commercial risks that can undermine long-term value. This tension is most evident in how companies talk about...
AI in Life Science Marketing: What’s Actually Working Beyond the Hype
Life science marketing teams are drowning in complexity. Regulatory compliance demands are tightening, scientific accuracy is non-negotiable, and sales cycles stretch 18-24 months or longer. Meanwhile, CMOs face relentless pressure to prove ROI faster while managing...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
Expansion at Oxford Science Park Boosts Innovation Ecosystem
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
Remote Stroke Surgery Breakthrough with New Robotic System
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Bacterial Movement Beyond Flagella: Surprising New Mechanisms Uncovered
Emerging Evidence of Alternative Motility For decades, scientists have believed that bacterial movement relied almost entirely on the rotation of whip-like flagella, which propel cells through liquids or across surfaces. However, new research has revealed that some...
The Passing of a Scientific Giant: James D. Watson
Renowned molecular biologist James D. Watson has died at the age of 97, his son and the Cold Spring Harbor Laboratory (CSHL) in New York confirmed. The scientist, best known for co-discovering the double helix structure of DNA in 1953, passed away following a brief...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
Expansion at Oxford Science Park Boosts Innovation Ecosystem
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
Remote Stroke Surgery Breakthrough with New Robotic System
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Bacterial Movement Beyond Flagella: Surprising New Mechanisms Uncovered
Emerging Evidence of Alternative Motility For decades, scientists have believed that bacterial movement relied almost entirely on the rotation of whip-like flagella, which propel cells through liquids or across surfaces. However, new research has revealed that some...
The Passing of a Scientific Giant: James D. Watson
Renowned molecular biologist James D. Watson has died at the age of 97, his son and the Cold Spring Harbor Laboratory (CSHL) in New York confirmed. The scientist, best known for co-discovering the double helix structure of DNA in 1953, passed away following a brief...
Featured Articles
Further News
The Rise of Cell and Gene Therapy Hubs Across Northern England
The life sciences landscape in northern England is undergoing a dynamic evolution, driven by the growing importance of advanced therapies such as cell and gene treatments. These innovative approaches, which aim to treat or cure diseases by intervening at the level of...
Current Talent, Skills and Infrastructure in the Life Science Industry
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
Rewriting the MND Playbook
How AI and Biomarkers Are Accelerating the Fight Against Motor Neurone Disease Every ninety minutes in the United Kingdom, someone receives a diagnosis of Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), and every ninety minutes, someone...
Challenges in Life Sciences Real Estate
The commercial real estate market serving the life sciences industry is currently undergoing a complex period of adjustment. The underlying dynamics that once propelled rapid growth, such as enthusiastic venture capital, strong demand from biotech and pharmaceutical...
Age Related T Cell Changes Weaken Vaccine Response in Older People
As the population ages, one of the major challenges facing public health is that vaccines tend to become less effective in older adults. A growing body of research increasingly points to specific changes in T cells, critical components of the immune system, as a key...
First Malaria Treatment Approved for Babies and Young Children
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
ProImmune Introduces ProVE SL Monomers to Boost T Cell Research
ProImmune has launched its new ProVE SL (Self-Loading) MHC Class I monomers, positioning these reagents as a next-generation tool for researchers studying antigen-specific CD8+ T cells. The announcement highlights the company’s aim to accelerate T cell research by...
Novo Nordisk Locks Horns with Pfizer in Late Bid for Metsera
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
Chinese Biotech Industry Shows No Signs of Slowing
The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...
AI and Early Detection of Dementia: Advancing Life Science Frontiers
Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
UK Life Sciences Growth Spreads Beyond London, Oxford and Cambridge
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
AI Giants Nvidia, Microsoft and Google Drive Innovation in Pharma R&D
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.